Number of items: 3.
Article
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. (2026)
Siamak Daneshmand,
Renata Zaucha,
James W.F. Catto,
Ben Tran,
Viraj A. Master,
Yair Lotan,
Geraldine Pignot,
Andrea Tubaro,
Nobuaki Shimizu,
Nikhil Vasdev,
Eugene K Lee,
Giuseppe Procopio,
Fernando Galanternik,
Lauren Crow,
Kris Deprince,
Vahid Naini,
Spyros Triantos,
Mahadi Baig,
Wei Zhu
and
Jodi K Maranchie
picture_as_pdf
Erdafitinib in BCG-treated high risk non-muscle invasive bladder cancer. (2024)
James W.F. Catto,
Ben Tran,
Morgan Roupret,
Juergen E. Gschwend,
Yohann Loriot,
Hiroyuki Nishiyama,
Joan P. Redorta,
Siamak Daneshmand,
Syed A. Hussain,
Hernan J Cutuli,
Giuseppe Procopio,
Valentina Guadalupi,
Nikhil Vasdev,
Vahid Naini,
Lauren Crow,
Spyros Triantos,
Mahadi Baig
and
Gary D. Steinberg
picture_as_pdf
Conference or Workshop Item
Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer (HR-NMIBC) With FGFR3/2 Alterations (alt) in THOR-2: Cohort 2 Interim Analysis Results. (2023)
James W.F. Catto,
Ben Tran,
Viraj A. Master,
Morgan Roupret,
Geraldine Pignot,
Andrea Tubaro,
Nobuaki Shimizu,
Nikhil Vasdev,
Juergen Gschwend,
Yohann Loriot,
Hiyoyuki Nishiyama,
Joan Redorta,
Siamak Daneshmand,
Yuji Miura,
Vahid Naini,
Lauren Crow,
Spyros Triantos,
Mahadi Baig
and
Gary D. Steinberg
